Regeneron Pharmaceuticals Financial Indicators Patterns

REGN -- USA Stock  

Quarterly Earning Report: November 5, 2019  

We recommend you to use Regeneron Pharmaceuticals fundamental analysis to see if markets are presently mispricing the firm. In other words this interface allows you to confirm available drivers of Regeneron Pharmaceuticals as well as the relationship between them. We found thirty-six available financial ratios for Regeneron Pharmaceuticals which can be compared to its competitors. To make sure the equity is not overpriced, please check all Regeneron Pharmaceuticals fundamentals including its Debt to Equity, Total Asset and the relationship between EBITDA and Earnings Per Share . Given that Regeneron Pharmaceuticals has Number of Shares Shorted of 2.27 M, we recommend you check out Regeneron Pharmaceuticals recent market performance to make sure the company can sustain itself down the road. Use Regeneron Pharmaceuticals to protect your portfolios against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly. Check odds of Regeneron Pharmaceuticals to be traded at $291.75 in 30 days.
2%2%

Chance of Financial Distress

Regeneron Pharmaceuticals has less than 2 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

Regeneron Pharmaceuticals Company Summary

Regeneron Pharmaceuticals competes with Vertex Pharmaceuticals, Dr Reddys, Zoetis, Perrigo Company, and Regeneron Pharmaceuticals. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7549 people.

Regeneron Pharmaceuticals Return On Equity vs Earnings Per Share

Regeneron Pharmaceuticals is rated third in return on equity category among related companies. It is rated third in earnings per share category among related companies creating about  0.74  of Earnings Per Share per Return On Equity. The ratio of Return On Equity to Earnings Per Share for Regeneron Pharmaceuticals is roughly  1.36 

Regeneron Pharmaceuticals Systematic Risk

The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Regeneron Pharmaceuticals correlated with the market. If Beta is less than 0 Regeneron Pharmaceuticals generally moves in the opposite direction as compared to the market. If Regeneron Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Regeneron Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Regeneron Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Regeneron Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

Regeneron Pharmaceuticals Thematic Clasifications

Cancer Fighters Idea
Cancer FightersView
Biotech Idea
BiotechView

Regeneron Pharmaceuticals October 16, 2019 Opportunity Range

Additionally take a look at Your Equity Center. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Search macroaxis.com